Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

9.84

Margin Of Safety %

Put/Call OI Ratio

0.57

EPS Next Q Diff

0.24

EPS Last/This Y

1.43

EPS This/Next Y

-0.45

Price

79.76

Target Price

87.63

Analyst Recom

1.65

Performance Q

30.08

Relative Volume

0.81

Beta

0.28

Ticker: IONS




19 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-11-17IONS73.280.620.5636851
2025-11-18IONS74.50.630.1737265
2025-11-19IONS74.030.630.1937321
2025-11-20IONS73.170.630.8637364
2025-11-21IONS76.140.630.3037558
2025-11-24IONS78.510.560.1632344
2025-11-25IONS80.920.551.2132506
2025-11-26IONS82.710.570.0233373
2025-12-01IONS820.560.9533739
2025-12-02IONS81.330.570.6434350
2025-12-03IONS81.730.570.1834461
2025-12-04IONS81.830.570.4234517
2025-12-05IONS81.740.570.0034565
2025-12-08IONS81.490.570.1034555
2025-12-09IONS78.820.570.2034602
2025-12-10IONS78.650.570.9734635
2025-12-11IONS79.110.570.4334684
2025-12-12IONS80.820.570.1334692
2025-12-15IONS79.720.570.5034782
DateSymbolLatestP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-11-17IONS73.32-186.1-221.4-1.67
2025-11-18IONS74.50-186.1-218.2-1.67
2025-11-19IONS74.00-186.1-208.4-1.67
2025-11-20IONS73.14-186.1-206.4-1.67
2025-11-21IONS76.09-178.1-227.9-1.61
2025-11-24IONS78.54-178.1-224.4-1.61
2025-11-25IONS80.93-178.1-223.8-1.61
2025-11-26IONS82.71-178.1-220.1-1.61
2025-12-01IONS82.01-178.1-207.6-1.61
2025-12-02IONS81.31-178.1-207.8-1.61
2025-12-03IONS81.84-178.1-213.8-1.61
2025-12-04IONS81.85-178.1-211.0-1.61
2025-12-05IONS81.68-178.1-210.5-1.61
2025-12-08IONS81.51-178.1- -1.61
2025-12-09IONS78.86-178.1-197.9-1.61
2025-12-10IONS78.64-178.1-210.0-1.61
2025-12-11IONS79.12-178.1-213.7-1.61
2025-12-12IONS80.79-178.1-219.7-1.61
2025-12-15IONS79.76-178.1-205.8-1.61
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-11-17IONS-49.573.497.87
2025-11-18IONS-49.573.497.87
2025-11-19IONS-49.573.497.87
2025-11-20IONS-49.573.497.87
2025-11-21IONS-50.533.497.87
2025-11-24IONS-50.53-1.777.97
2025-11-25IONS-27.21-1.777.97
2025-11-26IONS-27.21-1.778.95
2025-12-01IONS-27.69-1.828.95
2025-12-02IONS-27.69-1.828.95
2025-12-03IONS-27.69-1.828.95
2025-12-04IONS-28.15-1.828.95
2025-12-05IONS-28.15-1.828.95
2025-12-08IONS-28.15-1.748.96
2025-12-09IONS-28.05-1.748.96
2025-12-10IONS-28.05-1.749.84
2025-12-11IONS-28.05-1.749.84
2025-12-12IONS-28.05-1.749.84
2025-12-15IONS-28.05-1.729.84
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

[stock_market_widget type="chart" template="candlestick" assets="IONS" range="1y" interval="1d" price_field="close" heading="{symbol}" candle_border_width="1" candle_bullish_background_color="#21BA45" candle_bearish_background_color="#DB2828" candle_bullish_border_color="#21BA45" candle_bearish_border_color="#DB2828" axes_color="#000000" tooltip_text_color="#262626" tooltip_background_color="#ffffff" range_selector="true" volume_enabled="true" axes_enabled="true" tooltip_enabled="false" zoom_enabled="true" save_image_enabled="true" volume_bar_fill_color="#5679FF" api="yahoo-finance"]

Last Quarter Act. EPS

-0.8

Avg. EPS Est. Current Quarter

-1.2

Avg. EPS Est. Next Quarter

-0.56

Insider Transactions

-28.05

Institutional Transactions

-1.72

Beta

0.28

Average Sales Estimate Current Quarter

152

Average Sales Estimate Next Quarter

188

Fair Value

Quality Score

42

Growth Score

35

Sentiment Score

32

Actual DrawDown %

4.6

Max Drawdown 5-Year %

-60

Target Price

87.63

P/E

Forward P/E

PEG

P/S

13.35

P/B

20.8

P/Free Cash Flow

EPS

-1.71

Average EPS Est. Cur. Y​

-1.61

EPS Next Y. (Est.)

-2.06

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-26.46

Relative Volume

0.81

Return on Equity vs Sector %

-68.5

Return on Equity vs Industry %

-53.4

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

-205.8
[stock_market_widget type=”table-options” template=”gradient” color=”#5679FF” assets=”IONS” fields=”contract_symbol,type,strike,price,change_pct,implied_volatility,change_abs,open_interest,volume,in_the_money,bid,ask” pagination=”true” rows_per_page=”21″ sort_direction=”asc” alignment=”left” search=”true” sort_field=”strike” api=”yahoo-finance”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”IONS” options_type=”calls” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”IONS” options_type=”puts” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”IONS” options_type=”calls” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”IONS” options_type=”puts” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”IONS” options_type=”calls” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”IONS” options_type=”puts” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
Ionis Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 1069
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); Donidalorsen for patients with hereditary angioedema; and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 that has completed Phase 2 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.
stock quote shares IONS – Ionis Pharmaceuticals, Inc. Stock Price stock today
news today IONS – Ionis Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch IONS – Ionis Pharmaceuticals, Inc. yahoo finance google finance
stock history IONS – Ionis Pharmaceuticals, Inc. invest stock market
stock prices IONS premarket after hours
ticker IONS fair value insiders trading